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Highlights:
 Many anticancer compounds are unable to demonstrate pharmacological activity 
because they do not reach therapeutic concentration at the site of action
 Nanotechnology is a useful tool to improve the selective delivery of anticancer 
compounds to their site of action
 An interesting application of anticancer nanotechnology is represented by 
nanostructures spontaneously obtained by self-assembly of drug conjugates linked to 
a proper chemical entity
 The generation of hetero-NPs could be exploited for personalized combined 
treatment of different types of diseases
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Teaser: In this review we summarize the recent advances in nanoparticles obtained by self-assembly 
drug conjugates, a useful tool to improve drug delivery of anticancer compounds.
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Self-assembly drug conjugate preparation is a promising approach to improve activity and 
penetration through physiological barriers of potent small molecules, as well as to reduce any 
side effects. Drug conjugates can self-assemble in water to form nanoparticles (NPs) that 
offer several advantages because: (i) they are easy to obtain; (ii) they can reach high local 
drug concentration in tumor tissues; and (iii) they can reduce the side effects of drugs. All 
these factors improve drug pharmacokinetic properties. Here, we have reviewed the scope of 
nanotechnology-based self-assembly drug delivery approaches focusing on prodrugs able to 
form NPs by self-assembly; we have also summarized the current perspective and 
challenges facing the successful treatment of cancer.
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Introduction 
Many anticancer candidates are not able to demonstrate pharmacological activity despite 
their potent cytotoxicity because a minimum concentration is not reached at the site of action. 
In fact, most anticancer drugs have their targets within cells and tissues and the low partition 
coefficient of drugs can prevent the cell barrier permeation and consequently their cytotoxic 
effect. In recent years, nanotechnology has opened new perspectives for biological and 
biomedical applications to improve the selective delivery of anticancer compounds to their 
site of action. The use of nanotechnology in cancer treatment has some advantages [1]; in 
fact tumor blood vessels are highly disorganized because they are characterized by an 
inefficient lymphatic network and endothelial cells are less tight compared with normal 
tissues. Nanoparticles (NPs) can be preferentially delivered to the tumor site because of the 
enhanced permeation and retention (EPR) effect [2,3]. In addition to that, nanotechnologies 
can improve drug properties in several ways: by controlling release and distribution, by 
enhancing drug absorption and by protecting the drug from degradation. Micelles, liposomes, 
nanospheres, nanocapsules, nanorods, nanofibers, etc. are commonly used to load the 
drugs in the inner core or into the bilayer. A small but interesting niche inside anticancer 
nanotechnology is represented by nanosystems spontaneously obtained by self-assembly of 
conjugates composed of drugs linked to a proper chemical entity. The self-assembly of drug 
conjugates into NPs is a process that involves the formation of an ordered structure by 
spontaneous organization of building blocks as a consequence of specific local interactions. 
Assembly can be obtained with different methods and conditions but the key role of the 
amphilicity of the components is often fundamental. 
In recent years, the use of drug conjugates to obtain NPs has gained considerable attention 
[4–6]. These conjugates are usually obtained by a covalent coupling of the drug to 
biocompatible lipid moieties and the resulting molecules are able to form NPs by self-
assembly. NPs are usually characterized by different techniques to be easily compared to 
each other and to predict their biological efficiency [7]. Crucial parameters for NP 
characterization are the mean diameter, which influences their biodistribution and retention, 
and the surface charge, which is responsible for the interactions with the environment and 
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physical and chemical stability. Electron microscopy, dynamic light scattering (DLS), NP 
tracking analysis (NTA) and disk centrifugation are techniques that rely on different physical 
principles and sample preparation useful for particle size determination. The surface charge 
of NPs (zeta potential) is generally measured by laser doppler electrophoresis, which 
evaluates electrophoretic mobility of suspended NPs in the medium.
The aim of this paper is to review the latest literature (2009–2015) about prodrugs that can 
form NPs by self-assembly with a specific focus on the functionalization of anticancer 
compounds. We discuss the characteristics of self-assembly inducers and drug modification 
and NP biological evaluation. Figures 1 and 2 [s1]represent the structures of the mentioned 
self-assembly inducers and of the drugs, respectively. In Table 1 we summarize the 
mentioned drugs, the linker, the used self-assembly inducer and the corresponding 
characteristics of the obtained nanostructures together with the cancer cell lines used for the 
biological evaluation. Table 1 also shows the cases in which the in vivo tests were reported.
Self-assembly inducers
Self-assembly is a process that is mediated by noncovalent interactions between molecules 
via ionic bonds, H-bonding, hydrophobic interactions and van der Waals interactions. 
Different organic molecules, such as biocompatible polymeric chains or endogenous 
molecules (terpenes or polysaccharides), have been used as self-assembly inducers by 
covalent linkage to drugs. The drug and the self-assembly inducer can be directly attached or 
can be connected by a linker, which can be stable in serum but able to release the drug 
intracellularly. In the literature there are different examples detailing the use of biocompatible 
polymeric chains as self-assembly inducers for the formation of NPs.
Hydrophilic hyperbranched poly(ether-ester)
The use of biocompatible hydrophilic hyperbranched poly(ether-ester) (HPEE, 1, Figure 1) 
for the construction of an amphiphilic copolymer with the hydrophobic drug paclitaxel (7, 
Figure 2) has been reported recently. This conjugate is able to self-assemble in water to form 
NPs with a diameter of 50–120 nm. The copolymer paclitaxel–HPPE NPs are biodegradable 
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and they can be easily eliminated through excretion pathways in vivo because of the 
presence of many ester groups in the HPPE structure [8].
Polyethylene glycol
In another study, a multiarm-polyethylene glycol (PEG, 2) was employed for the delivery of 
anticancer drugs by the formation of self-assembled NPs. A folate-eight-arm PEG-betulinic-
acid was synthesized[s2] by connection of the poor water-soluble drug betulinic acid (8) 
(hydrophobic part), PEG (hydrophilic segment) and folate (target molecule). Also in this case 
the biocompatibility of the NPs is caused by the ester bonds in the conjugate that guarantee 
the drug release inside the cell. Multiarm-PEGs have some advantages compared with linear 
PEG such as the increase in molecular weight (low molecular weight PEG had been reported 
to be toxic for the kidneys) and the presence of many functional groups useful to improve the 
drug-loading capacity [9].
The use of a linker between the self-assembly inducer and the drug is useful to guarantee 
the release of the active molecule. In 2010, the covalent conjugation of a Pt(IV) prodrug (9) 
to a self-assembly inducer through an acid-responsive linker was exploited for the formation 
of NPs to improve the therapeutic efficacy of compound 9. In this case, a PEG-b-poly(L-
lactide) copolymer was used to induce self-assembly because of the advantages of 
polymeric NPs. These NPs can prolong the half-life of drugs in the systemic circulation, limit 
drugs side effects and release drugs in a controlled manner. The acid-responsive bond 
favors the control of the drug release in an environmentally sensitive manner. This approach 
would be useful to minimize the release of the drug in the blood (pH 7.4) and to facilitate the 
release inside the cells (pH 5–6). The prodrug conjugate, characterized by the presence of 
an acid-responsive hydrazone bond, was synthesized and it was demonstrated to form NPs 
by self-assembly via a precipitation method [10]. These NPs showed well-controlled drug-
loading yield, excellent acid-responsive drug-release properties and potent cytotoxic activity 
against ovarian cancer [11]. 
Recently, two different self-assembly inducers covalently bonded have been used to form 
NPs: a glycol chitosan chain (3) and a PEG block. In addition, the synthesized conjugate 
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consists of a functional 3-diethylaminopropyl isothiocyanate (DEAP) block and a 
photosensitizing drug, chlorine e6 (10). This conjugate self-organized in aqueous solution 
and some studies revealed that the glycol chitosan and PEG blocks are on the hydrophilic 
outer shell, and chlorine e6 is within the hydrophobic inner core. The advantages of using 
these self-assembly inducers are that a polysaccharide–drug conjugate is expected to 
provide an effective cancer therapy without affecting the safety of normal tissues and a PEG 
block could improve the stability of the drug conjugate in serum and the penetration into an in 
vivo tumor vasculature. In addition, this conjugate is characterized by the presence of a pH-
sensitive functional group that allows the release of the photosensitive drug in acidic 
conditions. In fact, it was previously shown that the pKb value of a glycol chitosan conjugate 
with DEAP is near 6.8. In this study it was demonstrated that, upon encountering the tumor 
environment, the diameter and the zeta potential of NPs change because of a variation in the 
pH value from 7.4 to 6.8. Also, the shape of NPs is affected by the pH variation – they are 
spherical under neutral conditions and become disentangled at pH 6.8 [12].
PEG was also used to induce self-assembly in a conjugate with beclin-1 (11), an autophagy-
inducing peptide. In particular, the amphiphilic poly(β-amino ester) copolymer used was 
composed of a hydrophobic monomer 1,6-hexanediol diacrylate, a pH-sensitive monomer 3-
(dibutylamino)-1-propylamine and a hydrophilic amino-terminated PEG. This copolymer was 
synthesized by Michael addition and characterized by 1H-NMR. The amphiphilic PEG-beclin-
1 polymers simultaneously self-assembled during dialysis from dimethyl sulfoxide into water 
into micelle-like NPs with a mean diameter of 32 nm. The efficacy of the pH-sensitive linker 
was confirmed by diameter measurements in different pH conditions – the dimensions of 
NPs increase considerably, implying that NPs disassociate and reorganize into larger entities 
under weakly acidic conditions [13].
Du et al. described the use of PEG as a self-assembly inducer in the synthesis of a dual pH-
sensitive polymer–doxorubicin (12) conjugate. The polyphosphoester was chosen as self-
assembly inducer because of its biodegradability and its previous uses in biomedical fields. 
The parental diblock copolymer monomethoxyl PEG-b-poly-(allylethylene phosphate) was 
easily prepared by ring-opening polymerization. The obtained conjugate self-assembled to 
Page 9 of 25
Ac
ce
pte
d M
an
us
cri
pt
give nanostructures in aqueous solution. To prove the efficacy of the pH-sensitive linker, the 
NPs were incubated at different pH values and the release of the free drug was monitored. 
Varying the pH from 7.4 to 5, the release of doxorubicin increased markedly indicating the 
sensitivity of NPs to endo and/or lysosomal pH. This suggests also that NPs can reduce 
premature drug release during circulation but specifically enhance intracellular drug release, 
which will be an important feature in cancer treatment [14].
In 2010, the use of an oligomer chain of ethylene glycol (OEG) was reported to form an 
amphiphilic phospholipid-mimicking prodrug with the anticancer drug camptothecin (13). The 
nature and the dimensions (eight repeating units) of the oligomer were selected as the water-
soluble part to maximize the drug-loading content and also to lower the critical vesicle 
formation concentration. In this case, a linker characterized by the presence of a thioester 
bond was used because of its ability of being easily hydrolyzed by esterases, which are 
abundant in cells. This conjugate was demonstrated to form NPs with a diameter of ~180 nm 
and a negative surface charge. The in vitro hydrolysis of the conjugate appeared slow at 
weakly acidic or neutral pH. Instead, in the presence of esterases, which are abundant in 
cytoplasm, the conjugate quickly hydrolyzed and released the free drug. Therefore, OEG–
camptothecin conjugate was confirmed to act as a prodrug for intracellular release of 
camptothecin [15].
Hyaluronic acid
Xin et al. reported the use of hyaluronic acid (HA, 4) as a self-assembly inducer for the 
formation of three types of paclitaxel-containing NPs. HA is a linear polysaccharide widely 
distributed throughout connective, epithelial and neural tissues. It is composed of two 
alternating units of D-glucuronic acid and N-acetyl-D-glucosamine. HA can be easily used as 
a self-assembly inducer because of its biocompatibility and biodegradability. In addition, it 
has a strong affinity to cell-specific surface markers overexpressed on the surface of many 
types of cancer cells, such as glycoprotein CD44 and receptor for HA-mediated motility. 
Furthermore, in this study different amino acids, such as valine, leucine and phenylalanine, 
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were used as spacers between the drug and the carrier to improve the release of paclitaxel 
from the conjugates. Amino acids are easily used as linkers owing to their bifunctional 
nature; in fact, they are characterized by the presence of a reactive carboxylic group to 
conjugate with the drug via an ester bond and the amino group that can be exploited for the 
linkage with the carrier. It was demonstrated that these conjugates with different aminoacidic 
linkers were able to self-assemble to form NPs characterized by a diameter of 275–285 nm 
[16].
Heparin
In 2009, valine, leucine and phenylalanine [s3]were used as spacers in another study in 
which the self-assembly inducer was heparin (5). Heparin is a biocompatible, biodegradable, 
and water-soluble natural polysaccharide with a structure consisting of variable sulfated 
repeating disaccharide units. Heparin has different biological activities including 
anticoagulant activity, inhibition of tumor development and angiogenesis. The synthesis of 
paclitaxel–heparin conjugates was reported and it was confirmed that they self-assembled in 
aqueous solution, forming approximately spherical NPs with a diameter of 140–180 nm 
composed of a paclitaxel core and a carrier shell [17]. 
Squalene
Squalene is a precursor of cholesterol biosynthesis and it belongs to the terpenoid family. Its 
inertness and biocompatibility justify the use of squalene derivatives (6) [3,6,18–35] and 
terpenes in general [36–39] for the preparation of self-assembling bioconjugates, as 
Couvreur reported in several papers. [s4]Squalene can be easily functionalized at its terminal 
double-bond owing to its compact conformation in very polar solvents. Indeed, the highly 
coiled conformation leaves [s5]the internal double-bonds sterically shielded whereas the 
terminal olefinic links are exposed and thus more reactive. So, the terminal double-bond can 
be converted into [s6]different functional groups such as aldehyde, carboxylic acid, alcohol or 
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amine. 
Recently, Couvreur and colleagues reported the formation of self-assembled NPs obtained 
by conjugation of squalene with two antiangiogenic multitarget tyrosine kinase inhibitors: 
semaxanib (14) and sunitinib (15) [19]. A pH-sensitive linker between the squalene chain and 
the active compound was introduced because many solid tumors are characterized by an 
acidic environment and because the intracellular release of the drug is favored by the acidic 
pH of endolysosomes. It was demonstrated that the bioconjugates self-assembled in NPs 
with narrow polydispersity in aqueous solution and an average diameter of 120–140 nm.
The introduction of a squalene tail was further exploited for the derivatization of known 
anticancer compounds such as paclitaxel, podophyllotoxin (16), camptothecin, epothilone A 
(17) and cyclopamine (18) with the inclusion of an alternative linker [40–42]. In this study, the 
squalene moiety and the active compound were connected by a disulfide-containing linker 
able to guarantee the drug release inside the cell. Indeed, cancer cells express high levels of 
detoxifying enzymes such as glutathione-S-transferases (GSTs) and glutathione (GSH) to 
protect themselves from toxic xenobiotics. Testing NPs in the presence of GSH, a 
progressive slight increase of size was evident and release (moderate) of the free drug was 
observed.
Amphiphilic drug–drug conjugate
An innovative self-delivery system in which drugs can be delivered by themselves without 
any carrier was developed by Huang et al. An amphiphilic drug–drug conjugate, consisting of 
the hydrophilic anticancer drug irinotecan (19) and hydrophobic anticancer drug chlorambucil 
(20) has been synthesized and demonstrated to be able to self-assemble in water to form 
NPs with a diameter of about 88 nm. As a result of the presence of an ester bond between 
the two drugs, the amphiphilic conjugate was able to release both the compounds after the 
hydrolysis of this bond in the tumor cells [43]. The same strategy was exploited in a recent 
study in which the hydrophilic gemcitabine (21) [s7]and the hydrophobic chlorambucil were 
linked via a hydrolyzable ester bond. The conjugate obtained was used to form NPs following 
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the nanoprecipitation technique [10] and it was demonstrated to form NPs [44].
Drugs: modification and biological evaluation
Different anticancer compounds were used for the formation of self-assembled 
nanostructures by exploiting the presence of the available functional groups for the linkage
with the self-assembly inducer. Paclitaxel (7) is a powerful antitumor agent mainly used for 
the treatment of breast and ovarian cancer. It inhibits cell replication in the late G2/M phase 
of the cell cycle by interfering with the depolymerization of microtubules. However, its poor 
water solubility and toxicity are disadvantages in the use of paclitaxel in cancer treatment. 
Paclitaxel has been functionalized at the 2ʹ position forming an ester bond, able to be easily 
cleaved to release the free drug. NPs obtained from the conjugate of paclitaxel with HPPE [8] 
were biologically evaluated on MCF-7 (breast cancer) and Tca8113 (oral squamous 
carcinoma) cell lines and they showed potent cellular growth inhibition abilities (Table 1). 
This result indicated that NPs are able to enter the cell and it is conceivable that the acidic 
pH and the enzymes inside the cell would lead to a slow release of paclitaxel which is 
responsible for the therapeutic effect. In vivo evaluation was made using two malignant 
tumor cell lines of MCF-7 and Tca8113 to establish tumor models. These evaluations 
showed that NPs exhibit antitumor effect with a lower toxic effect with respect to the free 
drug. When paclitaxel was linked to HA using different aminoacidic linkers [16], the obtained 
NPs were evaluated in vitro (MCF-7 cell line). It was demonstrated that NPs are more 
cytotoxic than free paclitaxel and flow cytometry analysis showed that NPs significantly 
enhance the extent of apoptosis-induced cell death. The same authors reported the 
formation of a conjugate with paclitaxel and heparin [17]. Also in this case, they 
demonstrated the activity of NPs on MCF-7 cells showing a better activity for the NPs than 
for the free drug. In vivo evaluation demonstrated that NPs show a similar ovarian tumor 
growth inhibition to paclitaxel and induce no bodyweight loss. The conjugation of paclitaxel 
with a squalenic tail through a disulfide-containing linker led to the formation of NPs that were 
biologically evaluated on MCF-7 cells [40]. It was demonstrated that the conjugation to 
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squalene decreased the cytotoxicity of the drug toward MCF-7 cells but it was confirmed that 
the disulfide bond improved the release of the toxic moiety.
Cisplatin has been widely used in the clinic to treat a variety of cancers such as ovarian, 
breast and small-cell lung cancer because of its potent activity to crosslink DNA upon 
entering the cells. However, cisplatin is vulnerable to attack by plasma proteins that 
deactivate the drug, leading to less therapeutic efficacy, and account for some severe side 
effects of cisplatin therapy. To improve the therapeutic index of cisplatin while minimizing its 
adverse side effects, cisplatin analog Pt(IV) prodrugs have been synthesized. Recently the 
functionalization of a cisplatin analog (9) with a PEG-polylactide copolymer that was 
covalently bonded to the hydroxylic groups of compound 9 was reported [11]. In vitro 
evaluation in the A2780 human ovarian carcinoma cell line showed an approximate 
sevenfold cytotoxicity increase for NPs with cisplatin analog 9 and this result could be due to 
the burst drug release in the acidic intracellular environment.
Chlorine e6 (10) is an attractive photodynamic therapy drug candidate because of its high 
absorption in the red spectral region and its cheapness compared with other porphyrin-based 
photodynamic therapy drugs. Other advantages of chlorine e6 are its long lifetimes in 
photoexcited triplet states and high molar absorption in the red region of the visible spectrum. 
Chlorine e6 was recently used for the synthesis of a biocompatible conjugate by the linkage 
with a polysaccharide exploiting a pH-sensitive linker for the release [12]. Biological 
evaluation of NPs on HeLa (cervical adenocarcinoma) cells demonstrated that higher levels 
of apoptosis are induced at pH 6.8 and 6.4 than at pH 7.4, whereas no noticeable difference 
in cell apoptosis with changes in pH values was observed in the presence of free chlorine e6.
Beclin-1 (11) is the peptide encoded by the human gene BECN1 and participates in 
autophagy regulation. It has been suggested that the overexpression of beclin-1 could inhibit 
tumor development but this peptide has some drawbacks. In fact, beclin-1 has a low 
chemical stability in vivo and it is characterized by a nonspecific biodistribution in tissues. To 
overcome these disadvantages, beclin-1 was engineered to have a thiol group at the N 
terminus to be easily conjugated with a pH-sensitive polymer [13]. The obtained NPs were 
biologically evaluated on MCF-7 cells and they showed significant cytotoxicity. It was also 
proved that NPs strongly induced autophagy and potentially led to autophagic cell death. In 
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vivo evaluation on MCF-7 cancer cells in a [s8]xenografted tumor nude mouse model 
demonstrated that the tumor size of tumor-bearing nude mice treated with NPs increased 
more slowly than that of the control group, demonstrating that NPs can kill tumor cells 
synergistically and effectively showing no extreme toxicity.
Doxorubicin (12), a widely used anticancer drug, was involved in the formation of a dual pH-
sensitive polymer conjugate [14]. Doxorubicin was linked to PEG through an acid-labile 
hydrazone bond. SK-3rd, a cancer stem cell line, was chosen to evaluate the efficacy of 
doxorubicin NPs and it was demonstrated that NPs enhanced the cellular internalization, 
subsequently released the free drug in the cells in response to the endo/lysosomal pH and 
thus inhibited the progression of cancer stem cells. Moreover Song et al. described the 
synthesis of a disulfide-linked doxorubicin drug–drug conjugate [45]. The in vitro cytotoxicity 
of doxorubicin NPs was weaker than that of the free drug but the antitumor efficacy of NPs 
evaluated in MCF-7-bearing mice was demonstrated to be higher than that of free 
doxorubicin.
In 2010, the hydrophobic anticancer drug camptothecin[s9] (13) was involved in the formation 
of an amphiphilic conjugate with a short ethylene glycol [15]. In addition, these NPs were 
loaded with the water-soluble drug doxorubicin to obtain a synergic effect. The cytotoxicity of 
these NPs was evaluated in SKOV-3 ovarian and MCF-7 breast cancer cell lines. 
Camptothecin–NPs were shown to be as cytotoxic as the free drug in the cell lines but 
doxorubicin-loaded NPs showed a higher activity than camptothecin–NPs, free camptothecin 
and doxorubicin demonstrating an additive or synergic anticancer activity of the two drugs 
involved in the NPs. In vivo evaluations were performed using athymic mice bearing 
intraperitoneal tumors and camptothecin–NPs were demonstrated to have a strong in vivo
anticancer activity.
Betulinic acid (8) is an anticancer compound that has some drawbacks such as poor water 
solubility, severe side effects for healthy tissues, rapid blood clearance and low tumor 
selectivity. However, the formulation of betulinic acid with [s10]NPs can overcome these 
problems. In particular, the conjugation with PEG induced the formation of NPs that were 
also loaded with the anticancer drug hydroxycamptothecin (22) [9]. The cytotoxicity of these 
NPs was evaluated on Lewis lung carcinoma (LLC) and A549 (human lung cancer) cell lines 
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and it was considerably higher than that seen with free betulinic acid. The combination 
therapy of NPs containing betulinic acid and hydroxycamptothecin results in a better in vitro 
activity than the two free drugs, suggesting a significant synergic effect of NPs by co-
delivering of the two drugs. In vivo efficacy of NPs was evaluated in xenograft models of lung 
tumors – tumor-bearing mice treated with NPs showed a clear survival advantage compared 
with the control-treated mice. The antitumor effect of NPs was higher than the ones for free 
betulinic acid and hydroxycamptothecin, and no signs of systemic toxicity were observed by 
monitoring bodyweight of mice. Moreover, the authors reported the preparation of NPs with 
the addition of a target molecule (folate). These NPs were demonstrated to be even more 
active in vitro and in vivo with respect to the NPs with no target molecules, confirming that 
these NPs could be delivered into cells more easily because of the presence of the folate.
Semaxanib (14) and sunitinib (15) are multitarget tyrosine kinase inhibitors but they have 
some side effects such as cardiotoxicity, severe cutaneous toxicities and hematotoxicity. The 
NPs obtained by the covalent linkage of these compounds with squalene were biologically 
evaluated on human umbilical vein endothelial cells (HUVECs), demonstrating that 
squalenoyl–sunitinib conjugate NPs showed notable cytotoxicity whereas semaxanib NPs 
were not active [19]. In addition, sunitinib NPs showed moderate cytotoxic activity against 
Mia Paca2 pancreatic cancer cells.
The water-soluble drug irinotecan (19), a camptothecin derivative and a potent DNA 
topoisomerase I inhibitor, and the water-insoluble chlorambucil (20), a DNA alkylating 
anticancer drug, were used to form an amphiphilic conjugate by an esterification reaction 
[43]. The NPs obtained were biologically evaluated using MCF-7 and HeLa cell lines. The 
cytotoxic activity of the drug–drug conjugate was demonstrated to be strongly dependent on 
its concentration – if the concentration is lower than the CAC value the cytotoxic activity is 
worse than the mixture of the two drugs but if the concentration is higher than the CAC value 
NPs showed a much better activity than the free drug mixture. This result suggested that the 
NPs enter the tumor cells and that the released irinotecan and chlorambucil have a synergic 
action. Furthermore, MCF-7 tumor-bearing mice were intravenously injected with irinotecan, 
chlorambucil, irinotecan/chlorambucil mixture and irinotecan/chlorambucil NPs; at the end of 
the experiments the tumor volumes in mice treated with NPs were much smaller than the 
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tumor volumes of all other mice, demonstrating that NPs produce a better tumor growth 
inhibition than the free drugs and their mixture. Moreover the hydrophilic drug irinotecan was 
recently used with the hydrophobic combretastatin A-4 to form a drug–drug conjugate. The 
obtained NPs were evaluated in MCF-7 and HUVEC cell lines and they showed a reduced 
cell survival ratio [46].
The use of chlorambucil in combination with another hydrophilic anticancer compound 
(gemcitabine, 21) was also reported in 2015 [44]. In vitro evaluation of NPs toward a number 
of cancer cell lines [SMMC-7721 (human hepatoma), HeLa, MCF-7, SGC-7901 (gastric 
cancer), U87 (glioblastoma)] confirmed an increased cytotoxic activity with respect to the free 
drugs. Imaging studies were performed and it was demonstrated that NPs are internalized in 
the cell. The in vivo anticancer activity of NPs was evaluated in the SMMC-7721 tumor-
bearing mouse model and it was reported that NPs have a high anticancer efficacy probably 
owing to the tumor targeting via the EPR effect. No significant bodyweight loss was 
observed, showing that NPs are well tolerated at the tested dose level.
It is worth highlighting the possibility to obtain hetero-NPs by mixing different drugs 
functionalized with the same self-assembly inducer. Couvreur and colleagues reported the 
formation of hetero-NPs by co-self-assembly of three squalene-based conjugates: 
gemcitabine–squalene (therapeutic component), rhodamine–squalene (fluorescent moiety) 
and biotin–squalene (targeting agent) [26]. These hetero-NPs demonstrated improved 
internalization in MCF7, M109 (murine lung cancer) and HeLa cell lines, which overexpress 
biotin receptors, and a stronger cytotoxic activity than nonbiotinylated NPs.
Our research group studied the formation of hetero-NPs by co-self-assembly of two 
squalene-based conjugates with the drugs paclitaxel (7) and cyclopamine (18) [42]. 
Biological evaluation of hetero-NPs on OVCAR5 (ovarian cancer), #83 and #110 (ovarian 
tumor-initiating), and U251 (glioblastoma) cell lines demonstrated a combined efficacy in 
apoptosis induction. Furthermore, we reported the formation of fluorescent hetero-NPs by co-
self-assembly of the above-mentioned drug–squalene conjugates with a 
tetramethylrhodamine–squalene conjugate. The demonstration of cell internalization was 
accomplished by the application of multiple fluorescence microscopy methods – three-
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dimensional confocal microscopy allowed the identification of fluorescent NPs in the 
cytoplasm of the cells and super-resolution microscopy (dSTORM) permitted calculation of 
the diameters of the bright particles.
Concluding remarks
This review has highlighted the recent progress in the field of prodrug conjugates able to 
form NPs by self-assembly. The simple functionalization of known anticancer compounds 
and the easy formation of NPs make this strategy simple to apply for different types of drugs 
and biological targets. This approach could improve drug biocompatibility and delivery 
efficacy. In addition, the functionalization of different known drugs with a cleavable linker and 
a proper lipophilic chain that induces self-assembly and the generation of hetero-NPs could 
be exploited for personalized treatment of different types of diseases [42–44]. The same 
strategy can be used for the preparation of fluorescent hetero-NPs that can help follow the 
dynamics of the delivery and it might be possible to trace these NPs in the cells by imaging 
[26,40].
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Figure legends
Figure 1. Structures of self-assembling inducers used for the formation of the conjugates. The anchor 
point used for the conjugation reaction with the active compound is highlighted in red.
Figure 2. Structures of anticancer compounds used as building blocks for the formation of the 
conjugate compounds. The anchor point used for the conjugation reaction with the self-assembling 
inducer is highlighted in red.
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Table 1. Nanoparticle properties
Abbreviation: n.a., not available[s17].
Drug Linker
Self-assembly 
inducer
Diameter 
(nm)
Z potential 
(mV) Cell line
In vivo
evaluation
Ref
s
9 Hydrazone bond 2 ~86 −33 A2780 [11]
Beclin-1 (11) 3-(Dibutylamino)-
1-propylamine
2 ~32 +24 MCF-7  [13]
Betulinic acid (8) 
Hydroxycamptothecin (22) - 2 108–125 
+5.3 to
[s11]+86 
LLC or A549  [9]
Camptothecin[s12] (13) β-Thioester 2 ~186 −4 SKOV-3MCF-7
 [15]
Camptothecin (13) Disulfide 6 ~195 −41 MCF-7 [40]
Chlorambucil (20)
Gemcitabine (21) - - ~160 +15.7
SMMC-7721
Hela
MCF-7
SGC-7901
U87
 [44]
Chlorambucil (20) 
Irinotecan (19)
- - ~88 +3.4
MCF-7
HeLa
 [43]
Chlorine e6 (10)
3-Diethyl
aminopropyl 
isothiocyanate
2 + 3 ~150 −8 HeLa  [12]
Cyclopamine (18) Disulfide 6 ~105 +37 U251 [42]
Cyclopamine (18)
Paclitaxel (7) Disulfide 6 ~229 +26 U251 [42]
Doxorubicin (12) - 6 ~130 +35 Mia PaCa-2
M109
 [39]
Doxorubicin (12) Hydrazone bond 2 ~27 n.a. SK-3rd [14]
Doxorubicin (12) Disulfide - ~89 n.a. MCF-7  [45]
Epothilone A (17) Disulfide 6 ~161 −56 MCF-7 [40]
Gemcitabine (21) - 6 ~130 n.a.
MCF-7
KB3-1
L1210 10K
 [23]
Gemcitabine (21) - 6 ~149 −25
HeLa
M109
MCF7
[26]
Gemcitabine (21) - 6 130–170 −6 Pancreatic  [35]
Gemcitabine (21) - 6 ~104 −6 L1210 10K [18]
Gemcitabine 
monophosphate (23)
- 6 50–150 n.a. L1210 10 K [21]
Irinotecan (19) Azobenzene 
bond
- ~196 n.a.
MCF-7
HUVEC
 [46]
Paclitaxel (7) Val, Leu, Phe 4 275–285 
+0.17 to
[s13]+0.43 MCF-7 [16]
Paclitaxel (7) Val, Leu, Phe 5 140–180 
−21 to 
−31[s14] MCF-7
 [17]
Paclitaxel (7) - 1 50–120 n.a.
MCF-7
Tca8113  [8]
Paclitaxel (7) Disulfide 6 ~103 −37 MCF-7 [40]
Paclitaxel (7) cis,cis-1,4-dienic 6 90–150
−19 to 
−[s15]26
A549 
HT-29
KB 3.1
 [22]
Paclitaxel (7) Ester bond 6 118–293
−44 to 
−36[s16] M109 [25]
Paclitaxel (7) - 6 149–225 n.a. A549 [41]
Podofillotoxin (16) Disulfide 6 ~184 −11 MCF-7 [40]
Semaxanib (14) Hemiaminal 6 ~141 −40 HUVEC [19]
siRNA (24) Maleimide-
sulfhydryl
6 ~165 −26 TPC-1
BHP 10-3
 [29]
Sunitinib (15) Hemiaminal 6 ~123 +23 HUVEC
Mia Paca2
[19]
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